Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) has been assigned an average rating of “Buy” from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $16.50.

Several analysts have recently commented on the stock. Zacks Investment Research cut shares of Trillium Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. HC Wainwright set a $7.00 price target on shares of Trillium Therapeutics and gave the company a “buy” rating in a research note on Monday, August 14th. Cowen and Company reissued a “buy” rating on shares of Trillium Therapeutics in a research note on Wednesday, July 5th. Finally, Ladenburg Thalmann Financial Services reissued a “buy” rating and set a $18.00 price target on shares of Trillium Therapeutics in a research note on Friday, June 9th.

Shares of Trillium Therapeutics (TRIL) opened at 5.05 on Friday. The firm has a 50-day moving average price of $4.62 and a 200-day moving average price of $5.30. The firm’s market capitalization is $54.51 million. Trillium Therapeutics has a 52-week low of $4.15 and a 52-week high of $17.70.

COPYRIGHT VIOLATION NOTICE: “Trillium Therapeutics Inc. (TRIL) Receives Consensus Rating of “Buy” from Analysts” was reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/trillium-therapeutics-inc-tril-receives-consensus-rating-of-buy-from-analysts/1565777.html.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. NEA Management Company LLC bought a new position in Trillium Therapeutics in the second quarter valued at approximately $4,619,000. Wells Fargo & Company MN boosted its stake in Trillium Therapeutics by 34.1% in the first quarter. Wells Fargo & Company MN now owns 17,700 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 4,500 shares during the last quarter. Creative Planning boosted its stake in Trillium Therapeutics by 1.1% in the second quarter. Creative Planning now owns 26,400 shares of the biotechnology company’s stock valued at $116,000 after acquiring an additional 300 shares during the last quarter. Victory Capital Management Inc. boosted its stake in Trillium Therapeutics by 40.0% in the first quarter. Victory Capital Management Inc. now owns 77,601 shares of the biotechnology company’s stock valued at $479,000 after acquiring an additional 22,171 shares during the last quarter. Finally, AWM Investment Company Inc. bought a new position in Trillium Therapeutics in the second quarter valued at approximately $4,415,000. 47.97% of the stock is currently owned by institutional investors and hedge funds.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.

Analyst Recommendations for Trillium Therapeutics (NASDAQ:TRIL)

Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.